Anticompetitive Patent Strategies by Pharmaceutical Companies
[Olga Gurgula] Abstract: Pharmaceutical companies have been increasingly exploiting the patent system to delay or even block generic competition. Some of these practices, such as ‘pay-for-delay’ agreements, have attracted the attention of competition authorities. However, other practices remain outside of competition authorities’ investigative activities in most jurisdictions.
